Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.
about
Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial.Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.Clinical effects of natalizumab on multiple sclerosis appear early in treatment courseNatalizumab in multiple sclerosis: discontinuation, progressive multifocal leukoencephalopathy and possible use in children.Intervening to reduce the risk of future disability from multiple sclerosis: are we there yet?Disability Progression After Switching from Natalizumab to Fingolimod or Interferon Beta/Glatiramer Acetate Therapies: A NARCOMS Analysis.Use of natalizumab in patients with active relapsing-remitting multiple sclerosis in Kuwait.
P2860
Q33736198-26520A41-074F-4546-94E0-A954133F74B9Q33965415-9CF4DB91-E321-4013-90CF-ED96C33FAC26Q34431300-EE1DDC8D-3AB2-4273-BCD3-35488AE97FA9Q36812543-21682B9F-A835-46F5-B19C-23BDA7B26064Q38619288-EC7ED476-C68D-427E-A943-3D8814AF8EE0Q38777286-9178D6E7-C998-4AAF-B133-AD2A233FA8F4Q41626879-F98F3388-D856-4355-B062-3B51010F834BQ42288520-8749CF4B-EFA7-432C-8629-36D50936BC2F
P2860
Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Sustained efficacy of natalizu ...... life data from a Swiss cohort.
@ast
Sustained efficacy of natalizu ...... life data from a Swiss cohort.
@en
Sustained efficacy of natalizu ...... life data from a Swiss cohort.
@nl
type
label
Sustained efficacy of natalizu ...... life data from a Swiss cohort.
@ast
Sustained efficacy of natalizu ...... life data from a Swiss cohort.
@en
Sustained efficacy of natalizu ...... life data from a Swiss cohort.
@nl
prefLabel
Sustained efficacy of natalizu ...... life data from a Swiss cohort.
@ast
Sustained efficacy of natalizu ...... life data from a Swiss cohort.
@en
Sustained efficacy of natalizu ...... life data from a Swiss cohort.
@nl
P2093
P50
P921
P1476
Sustained efficacy of natalizu ...... -life data from a Swiss cohort
@en
P2093
Bettina Schreiner
Björn Zörner
Heike Fischer
Michael Linnebank
Michael Weller
Nathalie Braun
Ulf Kallweit
P356
10.1097/WNF.0B013E31824644E6
P577
2012-03-01T00:00:00Z